DaVita shares surge 13.41% premarket after Q4 revenue and earnings beat estimates, with strong 2026 guidance exceeding expectations.

DaVita Inc. surged 13.41% in premarket trading following the release of stronger-than-expected fourth-quarter financial results and a bullish 2026 earnings forecast. The company reported $3.62 billion in revenue, a 9.9% year-over-year increase that exceeded the $3.51 billion consensus estimate, alongside adjusted earnings of $3.40 per share, 6.5% above projections. DaVita also raised its 2026 adjusted EPS guidance to a midpoint of $14.30, significantly outpacing Wall Street expectations. This performance countered a separate insider sale by Berkshire Hathaway and reinforced investor confidence in the company’s operational resilience and growth trajectory, particularly in light of its recent struggles with patient volume challenges. The sharp premarket rally, one of the stock’s largest moves in recent months, reflects a renewed optimism about DaVita’s ability to deliver on its long-term profitability and adapt to evolving healthcare delivery models.